Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail
-

Telecon, January 27, 2012 - HPC Cord Blood

 

 
RECORD OF TELEPHONE CONVERSATION
Submission Type: BLA    Submission ID: 125391/0    Office: OCTGT
Product:
Hematopoietic Progenitor Cells,Cord (HPC-C)
Applicant:
Clinimmune Labs
Telecon Date/Time: 27-January-2012 4:00 PM        Initiated by FDA? Yes
Telephone Number: -----(b)(4)------
Communication Categorie(s):
Product
 
Author: RAMANI SISTA
Telecon Summary:
Product – TNC Validation
FDA PARTICIPANTS:
Ramani Sista
Yong Fan
 
NON-FDA PARTICIPANTS:
Sharon Miller
Brian freed
Michael Aubrey
Linda Tapia
Sabine Stockinger
 
Trans-BLA Group: No
 Related STNs: None
Related PMCs: None
Background: ClinImmume submitted stability data with a ----------(b)(4)------------ processing method validation. All the units used for this validation were manufactured in 2005, therefore, the study is a retrospective data analysis, not a prospective validation. FDA initiated a telecom to request a prospective ---(b)(4)--- processing validation.
Telecon Body: FDA stated that all processing procedures include the -(b)(4)- processing, should be validated prospectively. ClinImmune confirmed that they did perform a prospective validation of the -(b)(4)- processing with RBC depletion efficiency, TNC recovery, ---(b)(4)--- viability, sterility, and (b)(4) data. FDA asked ClinImmune to submit the validation data for review and ClinImmue agreed.
-
-